Research News

Helq Gene Increases Risk of Rare Ovarian Cancer

Researchers in the UK have identified a gene in mice that, if faulty, may increase the chance of developing a rare type of ovarian cancer.  The findings were published in the journal Nature. The gene, known as Helq, helps repair damage to DNA that happens when it is copied as cells multiply. If the... 

Promising New Approach for Early Detection of Ovarian Cancer

Building on previously presented work, researchers at M.D. Anderson Cancer Center in Houston have published new findings that show that evaluating the change of CA-125 over time shows promise as a screening tool for early-stage ovarian cancer. OCRF grantees Karen Lu, MD and Robert Bast, MD were first... 

OCRF Researchers Review Preclinical Models Used in Ovarian Cancer Research

In a review article published online in Oncogene on August 12, OCRF-funded researchers provide a comprehensive review of pre-clinical models used in ovarian cancer research.  The authors, including OCRF grantees Ernst Lengyel, Daniela Matei, Ken Nephew, and Joanna Burdette, explore current experimental... 

Time Interval from Surgery to Chemo Impacts Prognosis in Ovarian Cancer

Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer. Data from 191 patients with stage III or IV ovarian cancer who underwent surgery followed by platinum-based chemotherapy... 

Analysis Points to New Cell Lines as Tumor Models for Ovarian Cancer Research

Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best.  OCRF grantee and SAC member Douglas Levine, MD was one of the authors of the paper. Cell lines derived from tumor... 

Progesterone and Estrogen Receptors are Prognostic Biomarkers for Some Ovarian Cancers

In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various subtypes of ovarian cancer.  To date, few biomarkers of... 

Use of Talc-based Powder Increases Ovarian Cancer Risk

The use of talc-based powder has been associated with an increased risk of ovarian cancer in some, but not all, studies.  In a new study published in Cancer Prevention Research, researchers found that “genital powder use is a modifiable exposure associated with small-to-moderate increases in risk... 

Supreme Court Strikes Down BRCA Gene Patents

In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v. Myriad Genetics, the court considered the validity of patents held by the Utah-based company Myriad Genetics for... 

ASCO News: Weekly Chemo Improves Quality of Life

In research presented at the American Society of Clinical Oncology meeting this week, researchers found that shortening the break between chemotherapy sessions improved quality of life for patients, without negatively impacting efficacy. Results from a randomized, phase III trial of over 800 women conducted... 

ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse

Research presented at the American Society of Clinical Oncology annual meeting this week suggests that adding the drug pazopanib (trade name Votrient) to standard treatment extends progression-free survival in ovarian cancer patients by 5.6 months. Pazopanib is an oral anti-angiogenesis drug already...